July 6, 2020 / 10:52 AM / a month ago

Emergent to make drug substance for J&J's COVID-19 vaccine candidate

July 6 (Reuters) - Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.

Johnson & Johnson had struck a deal with Emergent in April to use its manufacturing facilities and make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below